J. Goldman & Co’s Pfizer PFE Stock Holding History

J. Goldman & Co’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-268,600	Closed	-$7.54M	–	876
2026 Q1	$7.54M	Buy	+268,600	New	+$7.15M	0.22%	132
2025 Q4	–	Sell	-500,000	Closed	-$12.7M	–	691
2025 Q3	$12.7M	Buy	+500,000	New	+$12.3M	0.32%	95
2024 Q3	–	Sell	-697,500	Closed	-$19.5M	–	580
2024 Q2	$19.5M	Buy	+697,500	New	+$19.2M	0.55%	56
2024 Q1	–	Sell	-87,500	Closed	-$2.52M	–	495
2023 Q4	$2.52M	Buy	+87,500	New	+$2.65M	0.1%	172
2023 Q1	–	Sell	-50,000	Closed	-$2.56M	–	451
2022 Q4	$2.56M	Buy	+50,000	New	+$2.4M	0.13%	158
2022 Q3	–	Sell	-60,000	Closed	-$3.15M	–	465
2022 Q2	$3.15M	Buy	+60,000	New	+$3.06M	0.15%	156
2022 Q1	–	Sell	-40,500	Closed	-$2.39M	–	423
2021 Q4	$2.39M	Buy	+40,500	New	+$2.01M	0.13%	181
2021 Q3	–	Sell	-270,000	Closed	-$10.6M	–	432
2021 Q2	$10.6M	Buy	+270,000	New	+$10.5M	0.41%	63
2013 Q3	–	Sell	-71,356	Closed	-$1.9M	–	306
2013 Q2	$1.9M	Buy	+71,356	New	+$1.97M	0.19%	143

Other funds holding PFE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

J. Goldman & Co's PFE Position: Q2 2026 in Review

J. Goldman & Co sold out of Pfizer (PFE) in Q2 2026, closing a stake of 21,856 shares — an estimated $614K sold.

J. Goldman & Co first reported a position in PFE in Q2 2013 and held it in 11 quarters. The position peaked at $8.25M in Q4 2024. 2,827 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

J. Goldman & Co reported no remaining Pfizer position as of Q2 2026 after selling out during the quarter.
J. Goldman & Co sold 21,856 Pfizer shares in Q2 2026, an estimated $614K.
J. Goldman & Co first reported a position in Pfizer in Q2 2013 and held it in 11 quarters.
J. Goldman & Co's Pfizer position peaked at $8.25M in Q4 2024.
2,827 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on J. Goldman & Co's 13F filing for Q2 2026, filed 14 Aug 2026.